(UPDATED) There is no difference in in-hospital outcomes or longer-term mortality between patients undergoing revascularization with either a durable-polymer DES or newer technology with a ...

To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested including stents with bioabsorbable ...

Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year MARLBOROUGH, Mass., Boston Scientific reported positive, long-term data from the ...

CHICAGO, IL – Two new studies testing first- and second-generation drug-eluting stents (DES) with a bioabsorbable polymer have shown that the two stents are noninferior compared with a durable-polymer ...

Please provide your email address to receive an email when new articles are posted on . Boston Scientific announced that its bioabsorbable polymer stent platform has received a new indication from the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

A drug-delivering and self-dissolving arterial stent made by Boston Scientific has received Food and Drug Administration approval, the Marlborough-based company announced. Boston Scientific’s SYNERGY ...

CALGARY, Alberta--(BUSINESS WIRE)--Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an oversubscribed $27 ...

WASHINGTON - A novel study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable ...

This patent application has not been assigned to a company or institution. The following quote was obtained by the news editors from the background information supplied by the inventors: “It has ...